Penny Stocks
EOSE: Revenue Growth Faces the Gross-Margin Test Ahead of November 5 Earnings
Eos’s preliminary sales growth supports the manufacturing-ramp story, but deeply negative gross margins remain the key financial test.
Read the storyTagged: resultados
STORIES WITH TASTE
Penny StocksOCGN: Clinical Milestones and Cash Runway Put the Pipeline Ahead of the Earnings Headline
Ocugen’s November 4 update advances the clinical story, but its narrower net loss includes a large derivative-liability gain.
Penny StocksXMAX: A $30 Million Buyback Authorization Meets a Weaker Sales Picture
XMax authorized purchases below $5.50 per share, but the program is conditional and preliminary results show declining sales and a loss.
Penny StocksCMTG: Loan Resolutions and Lower Debt Put a Troubled Mortgage Portfolio in Focus
Claros resolved $409.5 million of loans and reduced financing, but losses and troubled-property exposure remain central to the story.
Penny StocksSTIM: Revenue Growth and Positive Adjusted EBITDA Give the Rally Substance
Neuronetics reported stronger third-quarter sales and positive adjusted EBITDA, while a GAAP loss and cash needs keep the turnaround unfinished.